Cachexia is a complex, multifactorial, and multi-organ metabolic syndrome found in the late stages of serious illnesses including cancer, kidney disease, and congestive heart failure.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
Published: 02 September 2021
Number of pages:27
This Market Spotlight report covers the Cachexia market, comprising epidemiology, key marketed and pipeline drugs, regulatory events, clinical trials, probability of success, and licensing and acquisition deals.
Adlumiz, an oral synthetic small molecule ghrelin mimetic, and Oxandrin, an orally active formulation of the anabolic steroid oxandrolone, are the only marketed drugs available for cachexia.
The majority of industry-sponsored drugs in active clinical development for cachexia are in Phase I, with only one drug in Phase III.
Therapies in active clinical development for cachexia focus on targets such as ghrelin receptor, growth differentiation factor 15, and GDNF receptor alpha-like (GFRAL). These drugs are administered via the oral and subcutaneous routes.
The overall likelihood of approval of a Phase I metabolic-other asset is 8.1%, and the average probability a drug advances from Phase III is 72.2%. Drugs, on average, take 9.1 years from Phase I to approval, compared to 9.6 years in the overall metabolic space.
The distribution of clinical trials across Phase I–IV indicates that the majority of trials for cachexia have been in the early and midphases of development, with 67% of trials in Phase I–II, and only 33% in Phase III–IV.
The US has a substantial lead in the number of cachexia clinical trials globally, while the UK leads the major European markets. Clinical trial activity in the cachexia space is dominated by completed trials. Helsinn and Bristol Myers Squibb have the highest number of completed clinical trials for cachexia, with six trials each.
Helsinn leads industry sponsors with the highest overall number of clinical trials for cachexia, followed by Bristol Myers Squibb and GlaxoSmithKline.
10 Cancer cachexia prevalence
10 Prevalence of cachexia due to other main causes
12 MARKETED DRUGS
14 PIPELINE DRUGS
18 KEY REGULATORY EVENTS
18 Japan’s Latest Batch Of New Drug Approvals Includes Adlumiz
19 PROBABILITY OF SUCCESS
20 LICENSING AND ASSET ACQUISITION DEALS
20 Faraday Pharmaceuticals Obtains Global Rights Of S-Oxprenolol
21 CLINICAL TRIAL LANDSCAPE
22 Sponsors by status
23 Sponsors by phase
LIST OF FIGURES
14 Figure 1: Overview of pipeline drugs for cachexia in the US
14 Figure 2: Pipeline drugs for cachexia, by company
15 Figure 3: Pipeline drugs for cachexia, by drug type
15 Figure 4: Pipeline drugs for cachexia, by classification
19 Figure 5: Probability of success in the metabolic-other pipeline
21 Figure 6: Clinical trials in cachexia
21 Figure 7: Top 10 drugs for clinical trials in cachexia
22 Figure 8: Top 10 companies for clinical trials in cachexia
22 Figure 9: Trial locations in cachexia
23 Figure 10: Cachexia trials status
24 Figure 11: Cachexia trials sponsors, by phase
LIST OF TABLES
9 Table 1: Drugs used for the treatment of cachexia
13 Table 2: Marketed drugs for cachexia
16 Table 3: Pipeline drugs for cachexia in the US
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726